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Abstract
The objective of the study is to analyze
the factors associated with the severity of
pruritus in patients with terminal chronic
kidney disease undergoing hemodialysis.
The methodology used is based on a
cross-sectional study in patients receiving
hemodialysis at the Centro Nacional de
Salud Renal. Severe pruritus was defined as
a score on the visual analogue scale greater
than or equal to 7, and the strength of asso-
ciation with the possible risk factors was
assessed by calculating prevalence ratios.
Regarding the results, 264 patients were
included, 59.9% were male, with a mean
time on hemodialysis of 10.26 ± 7.14 years.
75% experienced pruritus, of this group, 1
in 3 presented severe pruritus.
Hyperphosphatemia and the use of antihist-
amines were associated with a higher preva-
lence of severe pruritus (RP 1.71, 95% CI
1.09-267 and RP 2.39, 95% CI 1.51-3.75,
respectively). The positive serology for
Hepatitis C Virus was described as a protec-
tive factor for presenting severe pruritus
(RP 0.55, 95% CI 0.33 - 0.89). In conclu-
sion, severe uremic pruritus is a frequent
problem in patients with chronic terminal
kidney disease who have hyperphos-
phatemia and treatment with antihistamines
independently of the time they have been on
hemodialysis. 
Introduction
End-Stage Renal Disease is the final
stage of Chronic Kidney Disease (CKD)
and its incidence has increased considerably
in the last 30 years.1-3 The pruritus is
defined as an unpleasant and subjective sen-
sation that forces the individual to scratch, it
may be localized or generalized, and is a
frequent symptom in patients with terminal
chronic kidney disease on hemodialysis;4-7
it is the most reported dermatological symp-
tom, with a prevalence ranging between 20
and 90%, and, also, it significantly affects
the quality of life, the adherence the treat-
ment and the management of associated
comorbidities.8,9
The pathophysiology of pruritus in
patients with terminal chronic kidney dis-
ease is not well understood, however, a
series of studies have described several fac-
tors that could influence the pathogenesis of
the problem, including, BUN, serum calci-
um and phosphorus levels, high Parathyroid
Hormone (PTH) levels, a compromised skin
barrier, the dose of dialysis (kt/ V), the type
of membrane used by the dialysis equip-
ment, among others.6,9-12 Perhaps the most
relevant study, which managed to establish
the factors associated with pruritus in
patients with chronic kidney disease on
hemodialysis was the Daily Outcomes and
Practice Patterns Study (DOPPS); it was a
cohort of 18 801 patients on hemodialysis
from 12 different countries and it was deter-
mined that male patients, lung disease, con-
gestive heart failure, high phosphorus and
calcium levels, and low albumin levels,
experienced pruritus more severe than the
controls. They also established that there
was a slight increase in the severity of pru-
ritus in the first 10 years of illness.8 In Peru,
according to the Reporte del Registro
Nacional de Diálisis (RENDES) for 2015,
an average of 27 391 patients with terminal
chronic kidney disease are undergoing dyal-
isis.13 In this context, few studies have eval-
uated the presence and factors associated
with the severity of pruritus in these
patients. For this reason, it is necessary to
perform an investigation that can determine
the factors associated with the presence and
severity of pruritus in the peruvian popula-
tion undergoing hemodialysis.
Materials and Methods
Type of Research and design
Analytical cross-sectional study in
patients receiving hemodialysis from the
Centro Nacional de Salud Renal (CNSR).
Population
The study population included 282
patients with terminal chronic kidney dis-
ease on hemodialysis treated at the Centro
Nacional de Salud Renal (CNSR), regis-
tered in July 2017, of whom 264 agreed to
participate in the study. Minors and individ-
uals with a history of a previous dermato-
logical condition were excluded, as were
those who did not give informed consent.
Data Collection
A survey was developed that included
the age and sex of the patient, the time on
hemodialysis, and the Visual Analogue Scale
(VAS) for pruritus which determines that an
itch is severe when the score obtained is
greater than or equal to 7.14 This survey was
applied during the months of July and
August of 2017. The rest of the variables
were obtained directly from the database of
the Centro Nacional de Salud Renal (CNSR)
through a data collection sheet.
Processing and Data Analysis
The population was described using
measures of central tendency (mean and
median), distribution (Standard Deviation,
SD), and Interquartile Range (IQR) for
numeric variables. For the categorical vari-
ables, the frequencies and percentages were
reported. Next, a bivariate analysis was
conducted using chi-squared and Fisher’s
exact tests for the corresponding categorical
variables, and the significance level was set
at p<0.05. The crude and adjusted
Prevalence Ratio (PR) values were calculat-
ed with their respective confidence intervals
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using Poisson regression analysis with
robust error variance.
Ethical aspects
The study was approved by the Ethics
Committee of the Hospital Nacional
Edgardo Rebagliati Martins and by the
Research Committee of the Centro
Nacional de Salud Renal (CNSR). In addi-
tion, subjects had to sign a consent form in
order to ensure the anonymity of the study
and to secure the management of personal
information.
Results
264 individuals were recruited to partic-
ipate in the study. Regarding their clinical
profile, most patients were male (59.9%),
with an average age of 52.17 ± 15.32 years.
Likewise, the mean time of hemodialysis
was 10.26 ± 7.14 years. Furthermore,
73.9% (195/264) of the individuals reported
pruritus at the time of the study (Table 1).
In relation to the characteristics of the
patients who suffered pruritus, the average
score on the visual analog scale was 5.56 ±
2.3, and, according to the cut-off point pro-
posed in the study, 1 in 3 experienced
severe itching. Additionally, it was deter-
mined that 81 patients who had pruritus
symptom presented positive serology for
Hepatitis C Virus. Regarding calcium and
phosphorus values, 27.1% and 37.2% pre-
sented hypercalcemia and hyperphos-
phatemia respectively. On the other hand,
almost 1 in 4 patients suffered from anemia,
and with respect to the use of medications,
4.1% of patients used Gabapentin and
49.2% antihistamines to control their pruri-
tus (Table 2). Table 3 shows the results of
the bivariate analysis. It established that
high serum phosphorus levels, the dose of
dialysis, the use of gabapentin and the use
                             Article
Table 1. Characteristics of patients with
end-stage renal disease (n = 264).
                                                       n (%)
Age                            Mean (SD)          52.17 (15.32)
Gender                     Male                         158 (59.9)
                                  Female                   106 (40.1)
Time in dialysis       Mean (SD)           10.26 (7.14)
Pruritus                    Yes                           195 (73.9)
                                  No                             69 (26.1)
Table 2. Dialysis dose, pruritus intensity
and electrolyte values of patients with itch-
ing (n = 195).
                                                         n (%)
Hypercalcemia               Yes                       51 (27.1)
                                           No                       137 (72.9)
Hyperphosphatemia     Yes                       68 (35.8)
                                           No                       122 (64.2)
Hypoalbuminemia         Yes                       70 (37.2)
                                           No                       118 (62.8)
Excess of Ferritin          Yes                      184 (95.3)
                                           No                          9 (4.7)
Score (VAS)                    Mean (SD)       5.56 (2.29)
Itching (Intensity)        Severe                68 (34.9)
(n=195)                           Non severe       127 (65.1)
Anemia                             Yes                       46 (23.6)
                                           No                       149 (76.4)
Dialysis dose                   kt/V low               33 (18.1)
                                           (< 1,3)                        
                                           kt/V                     149 (81.9)    
                                           conventional 
                                           (≥ 1,3)
Use of gabapentin         Yes                         8 (4.1)
                                           No                       187 (95.9)
Use of antihistamines  Yes                       96 (49.2)
                                           No                        99 (50.8)
Hepatitis C                       Yes                       81 (41.5)
                                           No                       114 (58.5)
CRP (mg/dL)                   Mean (SD)       0.97 (2.05)
Some numbers may not add up due to missing values.
Table 3. Association between the characteristics and the severity of pruritus.
Characteristics of patients with terminal                   Pruritus patients (n=195)
chronic kidney disease                                 Severe (n=68) Non severe (n=127)                 p value
                                                                                                    n                             %                           n                         %                         
Age                                                         Mean (SD)                                          53.07                               15.23                            52.18                           15.12                         0.69*
Gender                                                  Male                                                         45                                   66.2                                76                              59.8                         0.39**
                                                               Female                                                    23                                   33.8                                51                              40.2                               
Hepatitis C serology                          Yes                                                           19                                   27.9                                62                              48.8                        0.005**
                                                               No                                                            49                                   72.1                                65                              51.2                               
Dialysis time                                        Mean (SD)                                          10.54                                6.59                              11.04                            7.62                          0.65*
Dialysis dose                                       kt/V low (< 1,3)                                     17                                   27.0                                16                              13.4                         0.02**
                                                               kt/V conventional (≥ 1,3)                    46                                   73.0                               103                             86.6                               
Laboratory characteristics
Anemia                                                  Yes                                                           15                                   22.1                                31                              24.4                         0.71**
                                                               No                                                            53                                   77.9                                96                              75.6                               
Hypercalcemia                                    Yes                                                           20                                   29.8                                31                              25.6                         0.53**
                                                               No                                                            47                                   70.2                                90                              74.4                               
Hyperphosphatemia                          Yes                                                           33                                   48.5                                35                              28.7                        0.006**
                                                               No                                                            35                                   51.5                                87                              71.3                               
Hypoalbuminemia                              Yes                                                           25                                   36.8                                45                              37.5                         0.92**
                                                               No                                                            43                                   63.2                                75                              62.5                               
Excess of Ferritin                              Yes                                                           64                                   94.1                               120                             96.0                         0.55**
                                                               No                                                             4                                     5.9                                  5                                4.0                                
CRP (mg/dL)                                       Mean (SD)                                           1.08                                 1.71                               0.85                             1.64                          0.35*
Use of medication
Gabapentine                                        Yes                                                            6                                     8.8                                  2                                1.6                          0.02**
                                                               No                                                            62                                   91.2                               125                             98.4                               
Antihistamines                                    Yes                                                           46                                   67.6                                50                              39.4                       0.0001**
                                                               No                                                            22                                   32.4                                77                              60.6                               
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of antihistamines were associated with
severe pruritus (p <0.05), defined as a score
greater than or equal to 7 on the analog
visual scale.
The results of the multivariate analysis
are shown in Table 4, after adjusting for sex,
age, time on hemodialysis, laboratory val-
ues and medication, it was established that
hyperphosphatemia (PR 1.78, 95% CI 1.13
- 2.79) and the use of antihistamines (PR
2.48, 95% CI 1.56 - 3.94), were associated
with a greater severity of pruritus.
Contrariwise, a positive serology for
Hepatitis C Virus (PR 0.55, 95% CI 0.33 -
0.89) was determined to be a protective fac-
tor for severe itching.
Discussion
Because pruritus constitutes a frequent
comorbidity in patients with terminal
chronic kidney disease and how it impacts
their quality of life, it is important to deter-
mine its prevalence in our population.
While several studies indicate that the
prevalence of pruritus ranges from 20 to
90%;8,9 in Peru, a previous study by
Herrera-Añazco et al. estimated a preva-
lence of uremic pruritus in hemodialysis
patients of 37.2%,12 a number much lower
than the one found in our investigation
(73.9%), besides, this also represents the
first peruvian study that has managed to
assess its severity. In that sense, the DOPPS
study, the most extensive and important
research in relation to uremic pruritus, not
only due to the large number of patients
included around the world, but also, in addi-
tion to reporting the prevalence of pruritus,
had also categorized itching according to
intensity, albeit using a Likert scale; accord-
ing to their findings, the prevalence of
“moderate to extreme” pruritus was 42%,8,9
a result very similar to ours.
Regarding the factors that are associat-
ed with the severity of pruritus, our multi-
variate analysis showed that hyperphos-
phatemia and the use of antihistamines were
associated with the presence of severe itch-
ing. The relationship between the use of
antihistamines and the presence of severe
pruritus is expected, given that a more
intense itching requires management
beyond topical therapy, for example, the use
of oral medications, including antihista-
mines, which according to some studies,
have shown to reduce uremic pruritus and
improve the quality of life.15 Nevertheless,
that antihistaines are generally considered
as ineffective in uremic itch and this could
be a major reason, why patients having
these medications suffered from more
severe itch. Our study also found that
hyperphosphatemia increases the preva-
lence of severe pruritus, which correlates to
other investigations, as well as being part of
the pathophysiology of chronic renal fail-
ure.8,9 Concerning comorbid hepatic infec-
tion, it has been described that patients on
hemodialysis and peritoneal dialysis show a
higher frequency of Hepatitis C infection
rather than Hepatitis B, nonetheless, both
viruses are associated with a greater pres-
ence of moderate to severe pruritus com-
pared to uninfected patients.9,16 It is known
that pruritus in individuals infected with
HCV is produced by virus-induced
cholestasis, as well as an increase in
chemokines (CCL2, CXCL1 and CXCL5)
and cytokines (primarily IL8), both as a
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Table 4. Crude and adjusted analysis between the characteristics and severity of pruritus in patients with end-stage renal disease.
Variables                                 Patients considered for multivariate analysis   (n=195) *                  
                                                                                                     PR** (CI 95%)                      p                        PR*** (CI 95%)                p
Characteristics of the participants                                                       
Age                                                          (years)                                                      1.00 (0.99 - 1.02)                           0.69                               1.01 (0.99 - 1.03)                     0.10
Gender                                                   Female                                                                  Ref                                       Ref                                           Ref                                 Ref
                                                                Male                                                           1.19 (0.79 - 1.81)                           0.39                               1.36 (0.87 - 2.14)                     0.18
Hepatitis C serology                           No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             0.55 (0.33 – 0.89)                         0.008                              0.55 (0.33 - 0.89)                    0.016
Dialysis time                                         (years)                                                      0.99 (0.97 - 1.02)                           0.63                               1.00 (0.97 - 1.04)                     0.88
Dialysis dose                                        kt/V conventional                                                Ref                                       Ref                                           Ref                                 Ref
                                                                kt/V low                                                     1.67 (1.11 - 2.51)                           0.01                               1.18 (0.69 - 2.01)                     0.55
Laboratory characteristics    
Anemia                                                   No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             0.92 (0.57 - 1.47)                           0.72                               0.99 (0.59 - 1.66)                     0.99
Hypercalcemia                                     No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             1.14 (0.76 - 1.73)                           0.53                               1.02 (0.70 - 1.51)                     0.88
Hyperphosphatemia                           No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             1.69 (1.17 - 2.46)                          0.006                              1.71 (1.09 - 2.67)                    0.018
Hypoalbuminemia                               No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             0.98 (0.66 - 1.46)                           0.92                               1.09 (0.69 - 1.69)                     0.71
Excess of Ferritin                               No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             0.78 (0.37 - 1.67)                           0.53                               0.81 (0.41 - 1.61)                     0.71
CRP                                                         (mg/dL)                                                     1.05 (0.96 - 1.14)                           0.32                               0.95 (0.78 - 1.15)                     0.58
Use of medications                 
Gabapentin                                           No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             2.26 (1.44 - 3.55)                         0.0001                             1.36 (0.79 - 2.32)                     0.26
Antihistamines                                     No                                                                           Ref                                       Ref                                           Ref                                 Ref
                                                                Yes                                                             2.16 (1.41 - 3.29)                         0.0001                             2.39 (1.51 - 3.79)                   0.0001
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result of high viral counts, which constitutes
an active HCV infection.17-20 In contrast to
what is described above, our study deter-
mines that a positive serology for HCV is a
protective factor for the development of
severe pruritus. This suggests that it is not
enough to describe a positive serological
result, but rather to determine disease activ-
ity by measuring viral load. 
We did not find an association between
severe pruritus and risk factors such as
hypercalcemia, hypoalbuminemia, anemia,
the presence of pro-inflammatory markers
such as CRP, among others.10,11,21 More
recent studies have included other variables,
for example, a high white blood cell count
or the presence of xerosis.22 In 2019 Ersoy
and Akyar found a higher pruritus severity
score both in patients over 65 years and
those in hemodialysis for 15 years or
more.23 These results differ from the find-
ings of our study where no association was
found between the severity of itching and
the patient’s mean time in hemodialysis.
In conclusion, pruritus is a common
phenomenon in patients with terminal
chronic kidney disease; its severity is asso-
ciated with a significant and progressive
deterioration in the quality of life of patients
undergoing hemodialysis. This study
demonstrates the magnitude of the problem
in the patients of the Centro Nacional de
Salud Renal (CNSR) and encourage the
need for interdisciplinary management
between nephrologists and dermatologists
to prevent and treat it.
Scope and limitations
In addition to reporting the prevalence
and severity of uremic pruritus in patients
with terminal chronic kidney disease, it is
also important to define its impact on the
quality of life of the patients. Many studies
have attempted to answer this question,
using a series of surveys that are difficult to
apply in daily practice. However, recently a
new 27-item questionnaire has been
designed, the UP-Dial, which assesses ure-
mic pruritus in all its dimensions (23). As a
continuation of this investigation, this new
tool could be validated in the previously
studied population. Likewise, it would be
interesting to make a comparison between
hemodialysis and peritoneal dialysis.
This study has some limitations. First,
because it is a cross-sectional study, a
causal relationship between the variables
studied cannot be established. Likewise, it
was not possible to analyze some factors
associated with severe uremic pruritus,
which could have enriched the analysis.
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